Loading clinical trials...

A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC) | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)

A Multicenter, Open-Label, Single-Arm Evaluation of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)

NCT01054456•Eisai Inc.

View on ClinicalTrials.gov

Summary

This study is designed to assess the safety and efficacy of palonesetron in preventing chemotherapy-induced nausea and vomiting (CINV) when administered to participants who have experienced either vomiting and or at least moderate nausea during their last cycle of low emetogenic chemotherapy.

Detailed Description

Palonosetron is currently approved for prevention of acute and delayed nausea and vomiting associated with initial and repeat CINV caused by moderate and highly emetogenic chemotherapy. This study is designed to assess the safety and efficacy of palonesetron in preventing CINV when administered to patients who have experienced either vomiting and or at least moderate nausea during their last cycle of low emetogenic chemotherapy. Palonosetron will be given intravenously approximately 30 minutes prior to the start of the chemotherapy regimen. Efficacy and safety including episodes of nausea, retching and or vomiting will be assessed over five 24 hour periods starting on Day 1 and ending on Day 6 in patient diaries. On Day 2 and Day 6 a FLIE (Functional Living Index- Emesis) assessment will also be completed in order to help evaluate the patient's quality of life from the start of the chemotherapy cycle through Day 6.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Provide written informed consent
•2. Male or female ≥18 years of age
•3. Histologically or cytologically confirmed malignant disease
•4. Karnofsky Index of 50%
•5. Experienced either vomiting and/or at least moderate nausea during their last cycle of LEC
•6. Scheduled to receive, on Study Day 1, a single dose of one of the qualifying LEC agents listed in the protocol.

Exclusion Criteria

•Subjects who meet any of the following criteria will be excluded from this study:
•1. Inability or unwillingness to understand or cooperate with the study procedures as determined by the Investigator
•2. Women who are pregnant, nursing or planning to become pregnant, women of childbearing potential who are not using an effective method of pregnancy prevention (including implants, injectables, combined oral contraceptives, some intrauterine devices, vasectomized partner or sexual abstinence), or women who have had a positive serum pregnancy test at screening or within 7 days prior to receiving chemo on Day 1. Non-childbearing potential includes women who are post-menopausal (12 months of amenorrhea with no other demonstrable cause, in the appropriate age group) or documented surgical sterilization, or hysterectomy at least 3 months before study start.
•3. Previous use of palonosetron in association with a LEC regimen
•4. Received more than one antiemetic agent for prevention of CINV (Chemotherapy-Induced Nausea and Vomiting) during their last cycle of LEC (other than dexamethasone or prednisone as outlined in number 7 below). The use of an antiemetic in addition to a corticosteroid during the last cycle of LEC is allowed if the corticosteroid is intended for the prophylactic treatment of taxane-related hypersensitivity or pemetrexed-related skin reactions as long as the corticosteroid regimen remains unchanged during the trial
•5. Suspected or confirmed ongoing vomiting for any organic etiology (e.g., food poisoning, gastroenteritis, etc)
•6. Received any drug with potential anti-emetic effect within 24 hours prior to the start of qualifying LEC agent
•7. Scheduled to receive an antiemetic (with the exception of administration of the palonosetron) at any time during the trial, listed below
•-5-HT3 receptor antagonists
•* NK1 receptor antagonists
+16 more criteria

Locations (9)

Sheridan Clinical Research

Sunrise, Florida, United States

Medical and Surgical Specialists

Galesburg, Illinois, United States

Orchard Healthcare Research Inc

Skokie, Illinois, United States

Trover Center for Clinical Studies; Merle Mahr Cancer Center

Madisonville, Kentucky, United States

Hematology- Oncology Associates of Rockland, PC

Nyack, New York, United States

Signal Point Clinical Research

Middletown, Ohio, United States

Scott and White Clinic- College Station

College Station, Texas, United States

Scott and White Healthcare- Round Rock

Round Rock, Texas, United States

Scott and White Memorial Hospital

Temple, Texas, United States

Key Dates

Start Date

October 27, 2009

Primary Completion Date

December 8, 2010

Completion Date

December 8, 2010

Last Updated

December 23, 2020

Enrollment

ACTUAL participants

Conditions

Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC

Interventions

palonesetron

DRUG